Diabetes Mellitus after Kidney Transplantation in the United States
Reads0
Chats0
TLDR
High incidences of PTDM are associated with the type of initial maintenance immunosuppression, race, ethnicity, obesity and hepatitis C infection, and it is a strong, independent predictor of graft failure and mortality.About:
This article is published in American Journal of Transplantation.The article was published on 2003-02-01 and is currently open access. It has received 1129 citations till now. The article focuses on the topics: Kidney transplantation & Cumulative incidence.read more
Citations
More filters
Journal ArticleDOI
Immunosuppressive Drugs for Kidney Transplantation
TL;DR: This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
Journal ArticleDOI
Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties
Christian P. Larsen,Thomas C. Pearson,Andrew B. Adams,Paul L. Tso,Nozomu Shirasugi,Elizabeth Strobert,Daniel G. Anderson,Shannon R. Cowan,Karen Price,Naemura Joseph R,John Emswiler,Jo Anne L. Greene,Lori A. Turk,Jürgen Bajorath,Robert M. Townsend,David Hagerty,Peter S. Linsley,Robert J. Peach +17 more
TL;DR: An attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4‐Ig, LEA29Y (belatacept), was constructed, resulting in a 10‐fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre‐clinical primate model.
Journal ArticleDOI
Diabetes mellitus after kidney transplantation in the United States.
TL;DR: The authors’ analysis of risk factors for new-onset diabetes and its clinical implications provides valuable evidence on this important issue, and highlights the need for management strategies that minimize risk of diabetes developing after transplantation.
Journal ArticleDOI
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
TL;DR: Reducing risk factors for patient death should be a major target to improve outcomes after renal transplantation and effort should be made to control cardiovascular diseases, malignancies and infections with improved use of immunosuppressive drugs.
Journal ArticleDOI
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003
Jaime A. Davidson,Alan H. Wilkinson,Jacques Dantal,Francesco Dotta,Hermann Haller,Domingo Hernández,Bertram L. Kasiske,Bryce A. Kiberd,Andrew J. Krentz,Christophe Legendre,Piero Marchetti,Mariana S. Markell,Fokko J. van der Woude,David C. Wheeler +13 more
References
More filters
Journal ArticleDOI
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C. Knowler,Elizabeth Barrett-Connor,Sarah E. Fowler,Richard F. Hamman,John M. Lachin,Elizabeth A. Walker,David M. Nathan +6 more
TL;DR: In this paper, the authors compared a lifestyle intervention with metformin to prevent or delay the development of Type 2 diabetes in nondiabetic individuals. And they found that the lifestyle intervention was significantly more effective than the medication.
Journal ArticleDOI
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Carl G. Groth,Lars Bäckman,José-Maria Morales,Roy Y. Calne,Henri Kreis,Philippe Lang,Jean-Louis Touraine,Kerstin Claesson,Josep M. Campistol,Dominique Durand,L. Wramner,Christina Brattström,Bernard Charpentier +12 more
TL;DR: Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus as discussed by the authors.
Journal ArticleDOI
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group
AD Mayer,Jean-Paul Squifflet +1 more
TL;DR: A significant reduction in the incidence of episodes of allograft rejection observed with tacrolimus therapy may have important long-term implications given the prognostic influence of rejection on graft survival.
Journal ArticleDOI
Association of diabetes mellitus and chronic hepatitis C virus infection.
Andrew Mason,Johnson Y.N. Lau,Nicole Hoang,Ke-Ping Qian,Graeme J.M. Alexander,Lizhe Xu,Linsheng Guo,Sheraj Jacob,Fredric Regenstein,Robert L. Zimmerman,James E. Everhart,Clive Wasserfall,Noel K. Maclaren,Robert P. Perrillo +13 more
TL;DR: A retrospective analysis of patients with chronic viral hepatitis and analyzed whether age, sex, race, hepatitis B virus (HBV) infection, HCV infection, and cirrhosis were independently associated with diabetes suggests a relatively strong association betweenHCV infection and diabetes.